Tirzepatide versus Mounjaro: Same Medicine, Different Name?

You searched 'tirzepatide versus Mounjaro', here's why that search exists

It happens because tirzepatide appears in clinical papers, NICE guidance and news coverage, while Mounjaro is the name on the packaging. Pharmacies list it as Mounjaro. Prescriptions say Mounjaro. The NHS medicines page for tirzepatide uses the generic name, and researchers publishing in journals do the same. Neither version is wrong, they simply sit in different registers. If you want a closer look at how the two names relate to the same medicine, our tirzepatide vs Mounjaro page walks through the distinction in plain terms.

The pen itself is a pre-filled KwikPen containing a once-weekly subcutaneous dose. Treatment starts at 2.5 mg, and a prescriber titrates from there in roughly four-week steps across six available strengths up to 15 mg. The dual GIP and GLP-1 receptor mechanism makes it the only medicine of its kind currently licensed for weight management in the UK. You can read more about how the treatment works on our Mounjaro overview page.

One quick check worth doing: if you find a website selling 'tirzepatide' without the Mounjaro branding and at a price that seems implausibly low, look the pharmacy up on the GPhC register. It takes under a minute. A legitimate UK pharmacy will be listed; if it isn't, walk away.

Mounjaro versus Wegovy: what the clinical evidence shows

This is the comparison most people are actually after. Both are licensed once-weekly injections for weight management in adults; both are available privately through a regulated pharmacy like nume. The meaningful difference is the mechanism: Mounjaro (tirzepatide) activates two gut-hormone receptors, GIP and GLP-1; Wegovy (semaglutide) targets GLP-1 alone.

In the SURMOUNT-1 trial, tirzepatide at 15 mg produced an average body-weight reduction of around 20–21% over 72 weeks among thousands of adults with obesity. The STEP 1 trial, published in the New England Journal of Medicine, recorded roughly 15% average loss with semaglutide 2.4 mg over 68 weeks. In the SURMOUNT-5 head-to-head trial (2025), tirzepatide produced greater average weight reduction than semaglutide 2.4 mg directly. Wegovy's newer 7.2 mg dose (approved by the MHRA in 2026) reported around 20.7% average loss, narrowing that gap considerably.

The table below summarises the factual differences. Numbers are from published trials and approved label information; 'average' figures reflect trial populations, not individual guarantees.

Which of these suits your situation is a clinical question, not a product preference. Our prescribers weigh your health history, any current medicines and your starting point before recommending one over the other. If you're curious how the comparison extends further, our page on GLP-1 versus tirzepatide covers the mechanistic detail.

What about Ozempic, Rybelsus and other names you may have seen?

A quick note on two medicines that frequently appear in the same searches. Ozempic is also semaglutide, but its UK licence covers type 2 diabetes management, not weight loss. Using Ozempic for weight loss would be off-label and is not something a regulated weight-management service prescribes for that purpose. Rybelsus is oral semaglutide, again for type 2 diabetes; it is a different product and different dose schedule from the Wegovy tablet approved in June 2026 for weight management. If you've been reading about retatrutide (a next-generation triple agonist still in trials) you can find a balanced look on our retatrutide versus tirzepatide page.

Metformin is another name that comes up, particularly for people with prediabetes or type 2 diabetes researching their options. Our Mounjaro versus metformin comparison covers the differences in mechanism, licensed use and evidence clearly.

The licensed landscape for weight management in the UK is: Mounjaro (tirzepatide), Wegovy injection (semaglutide 2.4 mg and 7.2 mg), and Wegovy tablets (oral semaglutide, approved June 2026). Our weight-loss treatments overview sets out all the options we currently offer.

Which suits you is a clinical decision, here's how that conversation works at nume

After you complete a free consultation, a prescriber on our clinical team reads your answers the same day. They look at your BMI, any existing health conditions, your medicines, and whether you've tried treatment before. That last point matters: if you're moving across from another provider, evidence of your current dose and how you've responded shapes the recommendation. Our clinical director's profile is on the team page if you'd like to know more about who reviews your case.

The prescriber may recommend Mounjaro, one of the Wegovy formats, or suggest a different starting point from the one you had in mind. That's not obstruction, it's what clinical review is for. There's no algorithm making that call. If approved, orders placed before 12pm are dispatched the same day and arrive the next working day via tracked DPD delivery. Getting started with Mounjaro explains the steps in full if you'd like to see the process before you begin.

Questions our team hears regularly are answered in our FAQ section. If something specific to your situation isn't covered there, get in touch and a member of the team will respond.